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CCR5 interaction with HIV-1 Env 
contributes to Env-induced depletion  
of CD4 T cells in vitro and in vivo
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Abstract 
Background: CD4 T cell depletion during HIV‑1 infection is associated with AIDS disease progression, and the HIV‑1 
Env protein plays an important role in the process. Together with CXCR4, CCR5 is one of the two co‑receptors that 
interact with Env during virus entry, but the role of CCR5 in Env‑induced pathogenesis is not clearly defined. We have 
investigated CD4 T cell depletion mechanisms caused by the Env of a highly pathogenic CXCR4/CCR5 dual‑tropic 
HIV‑1 isolate R3A.
Results: We report here that R3A infection induced depletion of both infected and uninfected “bystander” CD4 
T cells, and treatment with CCR5 antagonist TAK‑779 inhibited R3A‑induced bystander CD4 T cell depletion with‑
out affecting virus replication. To further define the role of Env‑CCR5 interaction, we utilized an Env‑mutant of R3A, 
termed R3A‑5/6AA, which has lost CCR5 binding capability. Importantly, R3A‑5/6AA replicated to the same level as 
wild type R3A by using CXCR4 for viral infection. We found the loss of CCR5 interaction resulted in a significant reduc‑
tion of bystander CD4 T cells death during R3A‑5/6AA infection, whereas stimulation of CCR5 with MIP1‑β increased 
bystander pathogenesis induced by R3A‑5/6AA. We confirmed our findings using a humanized mouse model, where 
we observed similarly reduced pathogenicity of the mutant R3A‑5/6AA in various lymphoid organs in vivo.
Conclusion: We provide the first evidence that shows CCR5 interaction with a dual‑tropic HIV‑1 Env played  
a significant role in Env‑induced depletion of CD4 T cells.
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Background
The depletion of CD4 T cells is a hallmark of HIV-1 
pathogenesis and AIDS progression [1]. Multiple studies 
have attempted to explain the depletion of CD4 T cells 
during HIV-1 infection. This can be broadly categorized 
into killing of uninfected “bystander” CD4 T cells, and 
“direct” killing of HIV-infected CD4 T cells [2]. Interest-
ingly, the rate of CD4 T cell decline is discordant with 
low level of productively infected cells in HIV-positive 
individuals. This suggests “direct” death of productively 
infected cells contributes minimally towards AIDS 
progression, and bystander cell killing appears to be the 
leading cause for CD4 T cell loss and AIDS progression 
[3]. The HIV-1 Env, also known as the gp120/gp41 gly-
coprotein, is expressed on the surface of infected cells or 
on HIV-1 virions and can interact with bystander cells 
expressing CD4. This interaction is critical for HIV-1 
entry and has been proposed to induce bystander CD4 T 
cell death [4–6].
HIV-1 strains can be broadly divided into two groups 
based on their Env tropism, each using CCR5 or CXCR4 
chemokine co-receptor for viral entry. The CCR5-
tropic HIV-1 Env interacts with CD4 and CCR5, infects 
CCR5+ CD4 T cells and macrophages, and is sensitive 
to CCR5 antagonists such as TAK-779. Likewise, the 
CXCR4-tropic virus interacts with CD4 and CXCR4, 
infects CXCR4+ CD4 T cells, and is sensitive to CXCR4 
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antagonists such as AMD-3100 [7, 8]. In addition, dual-
tropic HIV-1 strains have been reported that are capa-
ble to utilize both CCR5 and CXCR4 for entry [9–12]. 
R5-tropic HIV-1 dominates during the early stages of 
HIV-1 infection. In later stages of infection, X4-tropic 
viruses emerge and are thought to be responsible for the 
accelerated decline of CD4 T cells and AIDS progres-
sion [13]. The highly pathogenic phenotype of late stage 
X4-viruses has been related to the abundant expression 
of CXCR4 in virtually all CD4 T cells, whereas CCR5-
expressing CD4 T cells are mostly memory T cells [14]. 
However, in a significant proportion (>50  %) of AIDS 
patients, there is no co-receptor switch detected and 
their AIDS associated viruses are exclusively R5-tropic 
[15, 16]. Therefore, CCR5-tropic HIV-1 viruses can lead 
to AIDS progression but the mechanism remains unclear.
Previous reports have studied the pathogenic effect 
of HIV-1 Env binding to CCR5 by overexpression of 
R5-tropic Env on cell surface or by using recombinant 
R5-tropic gp120 proteins [4, 5, 17]. However, the patho-
genic effect of R5-tropic Env has not been studied in 
HIV-1 infection models, or directly compared to HIV-1 
viral load. In this report, we studied the Env pathogenic-
ity of a highly pathogenic dual-tropic HIV-1 strain (R3A) 
derived from a rapid progressor [9]. The Env gene of R3A 
is highly pathogenic and has been used for HIV-1 patho-
genesis studies [9–11]. The interaction of the V3 region 
of R3A-Env with the co-receptors and its specificity for 
either CCR5 or CXCR4 has been elucidated in a previ-
ous study [8]. We took advantage of a mutant R3A strain 
termed R3A-5/6AA from the study, which has lost the 
ability to bind and utilize CCR5 but can still use CXCR4 
for viral infection, therefore not affecting viral replica-
tion capability. Interestingly, the mutant R3A-5/6AA is 
substantially less pathogenic then the wild type R3A, as 
evidenced by the reduction of virus-mediated bystander 
CD4 T cells depletion. Supporting the functional rel-
evance of CCR5 interaction by R3A-Env in CD4 T cells 
pathogenesis, we found that the inhibition of Env-CCR5 
binding by CCR5 antagonistic drug TAK-779 reduced 
R3A-induced bystander CD4 T cells killing, whereas 
stimulation of the CCR5 receptor with agonistic drug 
MIP-1β increased the pathogenesis effect. We confirmed 
our findings in  vivo using a humanized mouse model, 
and we observed reduced bystander pathogenesis of 
the mutant R3A-5/6AA compared to the wild type R3A 
infection in CD4 T cells in the blood, spleen and bone 
marrow. We provide the first evidence in two physiologi-
cally relevant HIV-1 infection models that shows CCR5 
interaction with a dual-tropic HIV-1 Env plays a signifi-
cant role in Env-induced depletion of bystander CD4 T 
cells.
Results
A highly pathogenic HIV-1 isolate R3A induces depletion 
of both productively infected cells and bystander CD4 T 
cells in activated PBMCs.
We used a primary activated PBMC culture infection 
model to study the pathogenesis of the highly pathogenic 
dual-tropic HIV-1 strain (termed R3A) on CD4 T cells. 
Briefly, freshly isolated PBMCs (peripheral blood mono-
nuclear cells) were infected with an MOI of 0.01 for 3 h, 
followed by T cell stimulation with CD3/CD28 activation 
beads. The kinetics of virus-induced CD4 T cell deple-
tion can be accurately monitored (Fig. 1a), as CD4 T cell 
percentages and numbers in R3A infected PBMCs grad-
ually decreased over time (Fig.  1b). R3A pathogenesis 
was completely prevented by the fusion inhibitor T20, 
which effectively inhibited viral entry and replication as 
measured by intracellular HIV-1 p24 staining (Fig.  1c). 
Co-staining of intracellular p24 with a cell viability dye 
allowed us to analyze the percentage of dying cells in 
both productively infected and uninfected CD4 T cells 
(Fig.  1c). Compared to mock infection, we observed a 
significant higher percentage of dying cells in the p24(−) 
CD4 T cell populations at 6  days post R3A infection, 
therefore we termed it as bystander cell pathogenesis 
(Fig. 1d).
CCR5 antagonist TAK‑779 protects CD4 T cells 
from R3A‑induced bystander CD4 T cell depletion
Expression of R5-tropic HIV-1 Env proteins on cell sur-
face could induce the depletion of neighboring SupT1 
cells in a CCR5-dependent manner [5]. To investigate 
(See figure on next page.) 
Fig. 1 A highly pathogenic HIV‑1 isolate R3A induces depletion of both productively infected and bystander CD4 T cells. a HIV‑R3A infection in 
PBMC leads to efficient depletion of CD4+T cells. PBMCs were infected with R3A virus, and stimulated with anti‑CD3/CD28/CD2 activation beads 
at 3 h post infection and cultured in the presence of IL‑2 (20 U/mL). FACS Plots show CD4 and CD8 staining of populations gated on live CD3(+) T 
cells in PBMC at 6 days post infection (dpi). HIV‑1 fusion inhibitor T20 was used as negative control to prevent HIV‑1 infection. b Graphical summary 
showing kinetics of CD4 T cells depletion by R3A from 3 to 10 dpi. CD4 T cells are identified as live CD8 (−) CD3(+) population. Data are presented 
as %CD4 T cell survival relative to mock infection (top) and total CD4 T cell numbers (bottom) over time. c FACS gating strategies are presented. 
CD4 T cells were identified as CD3(+) CD8(−) population. Uninfected bystander CD4 T cells were identified as p24(−) cells and infected CD4 T cells 
as p24(+) cells (right graphs). Cell viability of both bystander and infected populations was quantified by co‑staining with a cell viability dye (left 
graphs). d Graphical summary of bystander p24(−) cell death at 6 days post infection by R3A. *p < 0.05
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how CCR5 interaction during dual-tropic R3A infec-
tion contributes to CD4 T cell depletion, we treated R3A 
infected cells with the CCR5 antagonist TAK-779. TAK-
779 is known to block HIV-1 Env interaction with CCR5 
and inhibit the infections of CCR5-tropic viruses [18]. 
As the dual-tropic R3A can also utilize CXCR4 for infec-
tion, we found R3A replication in CD4 T cells wasn’t sig-
nificantly affected by TAK-779 treatment, as measured by 
intracellular p24 staining or extracellular HIV-1 RT levels 
(Fig. 2a). Interestingly, CD4 T cell depletion was signifi-
cantly reduced by TAK-779 treatment (Fig. 2b). Further-
more, TAK-779 significantly reduced (p24−) CD4 T cell 
death to near background levels (Fig. 2c, d). However, cell 
death of HIV-1 infected (p24+) CD4 T cells was not sig-
nificantly affected by TAK-779 (Fig. 2c, d). This data indi-
cates blocking R3A-Env interaction with CCR5 reduced 
the pathogenesis on bystander CD4 T cells.
The binding of HIV-1 Env to the other co-receptor, 
CXCR4, has also been implicated in Env-induced cell 
death [19]. We therefore tested how CXCR4 binding by 
R3A Env affects viral pathogenesis using AMD3100, 
a CXCR4 antagonist [20]. Unlike TAK-779, the block-
age of CXCR4 usage by AMD3100 significantly reduced 
the entry and replication of R3A in PBMCs (Additional 
file 1: Fig S1a, b). As expected, the combined treatment of 
TAK-779 and AMD3100 completely inhibited R3A infec-
tion, similar to T20. This suggests the dual-tropic R3A, 
although capable of using either co-receptor for entry, 
relies more heavily on CXCR4 for replication in primary 
CD4 T cells. Although blocking CXCR4 usage by R3A 
also reduced CD4 T cell depletion (Additional file 1: Fig 
S1c), the interpretation here is difficult since virus repli-
cation was also significantly inhibited.
Ablation of CCR5 usage reduces dual‑tropic HIV‑1 
pathogenesis in PBMC infection
Our results with CCR5 antagonist TAK-779 treatment 
suggest the interaction of R3A-Env with CCR5 receptor 
contributed to CD4 T cells depletion during R3A infec-
tion. To expand this finding, we used a genetic mutant 
of R3A that is incapable of binding to the CCR5 recep-
tor. As published before [8], the R3A-5/6AA mutant 
(with two alanine substitutions in the 5th and 6th 
amino acids of Env V3 region) has lost its capability to 
infect CCR5-expressing cells but not CXCR4-expressing 
cells (Additional file 2: Fig. S2a). R3A-5/6AA could effi-
ciently utilize CXCR4 for virus entry and replication. 
Accordingly, we observed the virus replication was not 
significantly affected by its ablation of CCR5 usage, as 
R3A-5/6AA replicated to wild type R3A viremia levels 
as measured by both intracellular p24 staining and extra-
cellular HIV-1 genomic RNA levels (Fig.  3a; Additional 
file  2: Fig. S2b). We then compared the pathogenesis of 
wild-type R3A with R3A-5/6AA. As shown before, the 
highly pathogenic R3A can significantly deplete CD4 T 
cell levels, with 60 % depletion at 6 dpi and 90 % deple-
tion at 10  dpi. Remarkably, ablation of CCR5 usage by 
the mutant R3A-5/6AA significantly reduced CD4 T cell 
pathogenesis, with only 10 % depletion at 6 dpi and 35 % 
depletion at 10  dpi (Fig.  3b, c). This indicates R3A-Env 
binding with CCR5 strongly contributed to Env-medi-
ated CD4 T cell depletion. The reduced pathogenicity of 
R3A-5/6AA observed is not a consequence of reduced 
virus growth advantage, as R3A-5/6AA replicated to sim-
ilar levels as R3A (Fig. 3a). As shown before, R3A infec-
tion reduced the viabilities of both p24(−) and p24(+) 
CD4 T cells (Fig. 1c). Interestingly, the ablation of CCR5 
binding in R3A-5/6AA infection completely rescued 
death of p24(−) bystander CD4 T cells to background 
levels (Fig. 3d). The cell viability of p24(+) cells was not 
significantly different in R3A and R3A-5/6AA infection 
(Fig.  3d). Therefore, our data indicate R3A could effi-
ciently deplete both bystander and infected CD4 T cells, 
whereas R3A-5/6AA only induced perceivable pathogen-
esis in productively infected CD4 T cells. The reduced 
pathogenicity of R3A-5/6AA infection seen in Fig. 3c was 
therefore due to reduced bystander cell death, a conse-
quence of the loss of CCR5 binding capability by the Env 
mutant. We conclude R3A-induced bystander pathogen-
esis is dependent on the viral Env interaction with CCR5.
CCR5 agonist MIP‑1β enhances R3A‑5/6AA pathogenesis 
to promote bystander CD4 T cell depletion
MIP-1β is a CCR5-specific chemokine and agonist [21]. 
We investigated whether activation of CCR5 by MIP-1β 
could complement for the ablated Env-CCR5 interaction 
in R3A-5/6AA infection and therefore enhance bystander 
pathogenesis. We found MIP-1β treatment significantly 
(See figure on next page.) 
Fig. 2 CCR5 antagonist TAK‑779 protects CD4 T cell from R3A‑induced bystander CD4 T cell depletion a PBMCs were treated with CCR5 antagonist 
TAK‑779 (5 μM) before infection with R3A and maintained after infection. HIV‑1 viral replication in CD4 T cells was measured by intracellular p24 
staining or by extracellular HIV‑1 reverse transcriptase levels. b CD4 T cell depletion by R3A in the presence of TAK‑779 was measured by FACS 
analysis as described in Fig. 1b. %CD4 T cells over time relative to mock infected PBCMCs are presented. c Cell viability of bystander and infected 
CD4 T cells during R3A infection in the presence of TAK‑779 was analyzed as described in Fig. 1c. d Graphical summary of viral induced bystander 
cell death from c, presented as cell death percentage of p24(−) CD4 T cells at 6 days post infection. Experimental results were repeated with PBMCs 
from 2 different blood donors. *p < 0.05
Page 5 of 13Tsao et al. Retrovirology  (2016) 13:22 
Page 6 of 13Tsao et al. Retrovirology  (2016) 13:22 
Fig. 3 Ablation of CCR5 usage reduces dual‑tropic HIV‑1 pathogenesis in PBMC infection. a Intracellular p24 staining and FACS analysis was used to 
quantify viral replication in infected PBMCs. Infected (p24+) CD4 T cell numbers were calculated by multiplying the percentage of (p24+) cells with 
total CD4 T cell numbers at each time point (left). RT‑qPCR analysis of HIV‑1 genomic RNA levels was used to measure extracellular viral replication of 
R3A and R3A‑5/6AA in infected PBMCs (right). b Representative FACS Plots are presented showing CD4 and CD8 populations gated on live CD3(+) 
T cells in PBMC at 6 days post infection. HIV‑1 fusion inhibitor T20 treatment was used as negative control. c Kinetics of CD4 T cell depletion by R3A 
versus R3A‑5/6AA was analyzed as described in Fig. 1b. CD4 T cell survival are measured as %CD4 T cells in infected PBMCs relative to mock infec‑
tion (top), or live CD4 T cell numbers (bottom) over time. d p24(−) and p24(+) CD4 T cell death in R3A and R3A‑5/6AA infected PBMCs are quanti‑
fied at 6 days post infection, as described in Fig. 1C. FACS plots (left) and graphical summary (Right) from a representative experiment are presented. 
Experimental results were repeated with PBMCs from 3 different blood donors. *p < 0.05
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increased the death of p24(−) CD4 T cells in R3A-5/6AA 
infected PBMC cultures, without affecting the viability of 
p24(+) CD4 T cells (Fig. 4a, b). Accordingly, MIP-1β also 
decreased the CD4 T cell survival (Fig. 4c). We conclude 
MIP-1β binding to CCR5 could partly mimic R3A’s Env 
interaction with CCR5 and increase bystander CD4 T 
cell depletion.
Ablation of CCR5 usage reduces pathogenesis of dual 
tropic HIV‑1 in a humanized mouse model in vivo
To confirm that Env-CCR5 interaction contributes to 
HIV-1 bystander pathogenesis in a relevant HIV-1 infec-
tion model in vivo, we compared the infection and patho-
genesis of R3A with R3A-5/6AA in the huHSC mice, a 
suitable small animal model to study HIV pathogenesis 
in  vivo [22]. Similar to infected PBMC cultures, R3A-
5/6AA replication was delayed initially at 1  week post 
infection but reached similar viremia levels as R3A at 2 
and 3 weeks post infection as measured by HIV genomic 
RNA levels in the blood and intracellular p24 staining 
of CD4 T cells in the spleen (Fig. 5a). When analyzed at 
3  weeks post infection, we found R3A-5/6AA was sig-
nificantly less pathogenic than R3A in vivo, with reduced 
CD4 T cell depletion in the blood, spleen and bone mar-
row (Fig.  5b). Furthermore, R3A infection resulted in 
higher cell death of p24(-) CD4 T cells than R3A-5/6AA 
infection in vivo (Fig. 5c). The viability of infected p24(+) 
CD4 T cells was similar in R3A and R3A-5/6AA infection 
(Fig.  5c). These findings indicate R3A Env interaction 
with CCR5 induced bystander CD4 T cell pathogenesis 
in HIV-infected humanized mice.
Discussion
Multiple viral and host factors determine the variability 
in HIV-1 disease progression [17, 23–26]. Cellular tro-
pism and receptor/co-receptor usage for viral entry are 
major factors influencing HIV pathogenesis. Despite 
extensive research, the exact mechanism of how those 
factors contribute to the gradual loss of CD4 T cells is 
still enigmatic. Bystander CD4 T cell death plays a major 
contribution towards AIDS progression. A recent report 
has revealed a mechanism for HIV-induced CD4 T cell 
depletion, which involves abortive non-productive HIV 
infection in resting CD4 T cells, followed by IFI16 acti-
vation and caspase-1 dependent pyroptosis [27–29]. 
Besides the abortive RT products in non-productively 
infected resting cells, several HIV-1 proteins have also 
been reported to contribute to the depletion of bystander 
(uninfected and non-productively infected) CD4 T cells, 
including the Env [4, 5, 17, 19], Vpr [30], Nef [31, 32] and 
Tat [33]. The Env protein is of specific interest in medi-
ating AIDS progression, and has been implicated as an 
important cytopathic determinant of AIDS-associated 
CCR5-tropic viruses [34, 35]. CCR5 expression levels 
on cell surface correlate with increased host susceptibil-
ity to R5-tropic Env-induced apoptosis [5]. Interestingly, 
humanized mice engrafted with CCR5Δ32+/− donor 
cells supported HIV-1 replication with reduced CD4 T 
cell depletion [36]. It has been difficult to directly define 
the role of CCR5 interaction in HIV-induced CD4 T cell 
depletion because CCR5 interaction is required for the 
replication of CCR5-tropic HIV-1. Our findings using 
a dual-tropic HIV-1 confirmed that the interaction 
between CCR5 and HIV-1 Env is a critical determinant 
of bystander CD4 T depletion. The dual-tropic R3A virus 
is known to be highly pathogenic, depleting thymocytes 
through multiple mechanisms including fusion-induced 
apoptosis [10] and fusion-independent interferon-medi-
ated mechanism [11]. In humanized mice, R3A infection 
caused rapid depletion of both infected and uninfected 
CD4 T cells [22, 37]. Using an Env mutant R3A-5/6AA 
that has lost interaction with CCR5, we were able to 
show that the ablation of CCR5 usage by the dual-tropic 
R3A virus effectively decreased viral pathogenicity 
on bystander CD4 T cells in activated PBMC cultures 
(Fig. 3) and in humanized mice (Fig. 5). Notably, ablation 
of CCR5 usage did not significantly affect the killing of 
productively infected CD4 T cells (Figs.  3d, 5c), corre-
sponding with previous reports that the R3A Env fusion 
activity [10] and other HIV-1 proteins can promote death 
of directly infected cells [38, 39]. It is of note that the rep-
lication of mutant R3A-5/6AA was lower compared to 
R3A at early time points (Fig. 5a). The delayed replication 
peak may have contributed to the decreased pathogenic-
ity of the mutant virus at early time points.
Signal transduction through Env-CCR5 interaction 
on bystander CD4 T cells may contribute to viral patho-
genesis [17, 24]. Here we showed that CCR5 antagonist 
TAK-779 decreased R3A-induced bystander CD4 T 
cells depletion (Fig.  2), whereas CCR5 agonist MIP-1β 
increased bystander pathogenesis (Fig.  4), supporting 
a role for CCR5 stimulation/signaling in R3A patho-
genesis. Mechanistically, HIV-1 Env binding to CCR5 
induces a signaling cascade including calcium influx, 
Pyk2 phosphorylation and downstream activation of p38 
MAPK pathway [40–42]. Using a p38 inhibitor, Li et al. 
has shown that CCR5 engagement by HIV-1 Env leads 
to p38 activation and Fas- and caspase-dependent cell 
death [43]. The signaling through CCR5 by the R3A Env 
and subsequent p38 activation, together with Env bind-
ing to CD4, may be involved in R3A induced bystander 
T cell killing. MIP-1β binds to CCR5 and is also known 
to similarly activate Pyk2 and p38 MAPK pathways [42, 
44], which may mimic the Env-CCR5 interaction and 
contribute to bystander cell death, as shown in Fig. 4. In 
addition to CCR5, the interaction of CXCR4 with HIV-1 
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Env is also known to contribute to Env-mediated cell 
death [19]. Although treatment with CXCR4 antagonist 
AMD3100 decreased R3A pathogenesis, the interpre-
tation in this study is difficult since AMD3100 also sig-
nificantly inhibited R3A replication (Fig S1). Therefore, 
like most dual-tropic viruses, R3A relies more heavily 
on CXCR4 than CCR5 usage for infection in primary 
PBMC. It remains to be determined whether CXCR4 
binding by R3A Env also contributes to CD4 T cell death 
during infection. Lastly, the cooperative engagement 
of R3A Env to both CCR5 and CXCR4 may result in 
stronger binding of the Env to CD4 T cells, which may 
directly affect Env-mediated cell death. Loss of CCR5 
engagement in our studies may have resulted in a weaker 
Fig. 4 CCR5 agonist MIP‑1β enhances R3A‑5/6AA pathogenesis to promote bystander CD4 T cell depletion PBMCs were infected with R3A‑5/6AA 
virus and treated with recombinant MIP‑1 β (200 ng/mL) at 3 h post infection. At 6 days post infection, viabilities of p24(−) and p24(+) CD4 T cell 
were measured as described in Fig. 1c. a Representative FACS plots and b graphical summary are presented. c %CD4 T cells survival at 6 days post 
infection was measured by gating on live CD8(−) CD3(+) cells. *p < 0.05
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binding to CD4/CXCR4 and therefore a reduced Env 
pathogenicity. Accordingly, MIP-1β may have enhanced 
this Env-CXCR4 interaction and therefore contributing 
to the increased cell death.
In summary, we provide the first evidence in relevant 
infection models with a dual tropic HIV-1 that can effi-
ciently infect primary human PBMC when its binding 
to CCR5 is blocked genetically or pharmacologically, 
demonstrating CCR5 interaction with dual-tropic 
HIV-1 Env played a significant role in Env-induced 
depletion of bystander CD4 T cells. Our findings sug-
gest that drugs such as Maraviroc or gene therapy tar-
geting CCR5 interaction with HIV gp120 can not only 
prevent R5-mediated HIV-1 entry, they can also reduce 
Env-mediated CD4 T cell depletion and AIDS disease 
progression.
Conclusion
We provide the first evidence in relevant infection mod-
els that shows CCR5 interaction with a dual-tropic HIV-1 
Env played a significant role in Env-induced depletion of 
CD4 T cells.
Methods
Cell cultures
Total PBMCs were isolated from peripheral blood of 
healthy donors by Ficoll-Paque™ Plus (GE Healthcare) 
density gradient centrifugation and maintained in RPMI 
1640 (Gibco) supplemented with 10  % FBS, 1X Antibi-
otic–Antimycotic (Invitrogen) and 1  µM l-glutamine. 
T cell activation in PBMCs were performed with CD3/
CD2/CD28 activation beads (Miltenyi Biotech) and cul-
tured in RPMI medium described above containing 20 U/
mL recombinant human interleukin-2 (IL-2). HEK293T 
cells were cultured in DMEM (Gibco) containing 10  % 
FBS and 1X Antibiotic–Antimycotic. MAGI cells (NIH 
AIDS Research and Reference Reagent Program) were 
maintained in the same medium plus selection antibiot-
ics [45].
HIV‑1 virus production
X4/R5 dual tropic HIV-1 (strain pNL4-R3A) was gen-
erated by cloning the R3A Env gene in the background 
of pNL4-3 proviral genome as previously described [9]. 
The mutant R3A proviral strain (pNL4-R3A-5/6AA) was 
generated and kindly provided by Dr. James Hoxie [8]. 
HIV-1 virions were produced by CaCl2-BES (N,N-bis[2-
hydroxyethyl]-2-minoethanesulfonic acid) transfection of 
proviral plasmids in 293T cells. 293T cells cultured on a 
10 cm plate were transfected with 30 μg DNA plasmids 
of pNL4-R3A or pNL4-R3A-5/6AA, and cell superna-
tants were harvested at 48 h post transfection and passed 
through 45  µm membrane filter. Concentration of virus 
stocks were measured by p24 ELISA assay (Frederick 
National Laboratory for Cancer Research—AIDS and 
Cancer Virus Program). Infectious titers were deter-
mined in CCR5-expressing or CXCR4-expressing MAGI 
cells as previously described [45].
HIV‑1 infection of PBMC cultures
Unless indicated otherwise, infections of PBMCs with 
R3A or R3A-5/6AA was performed by infecting 1 × 106 
freshly isolated PBMCs with MOI of 0.01 (as titered in 
CXCR4-expressing MAGI cells) for 3 h at 37 °C in a total 
volume of 100 µL supplemented RPMI medium contain-
ing polybrene (8 µg/mL). At 3 h post infection, viral inoc-
ulum were washed with PBS, activated with CD3/CD28 
activation beads as described above, and cultured at con-
centration of 0.5 × 106 cells/mL in the presence of IL-2 
(20  U/mL). When indicated, PBMCs were treated with 
10 µg/mL fusion inhibitor T20 (NIH AIDS Reagents Pro-
gram) before infection and maintained throughout the 
experiment. TAK-779 and AMD3100 (NIH AIDS Rea-
gents Program) were treated before infection at an IC90 
dose of 5 and 2 µM respectively, as determined before in 
U373-CD4-CCR5/CXCR4 cells. Treatment with 200 ng/
mL MIP-1β started at 3 h post infection and maintained.
Flow cytometry analysis
Aliquots of infected PBMC samples (~1E5 cells) were 
collected for analysis at the indicated time points post 
HIV-1 infection. Staining for cellular surface CD3, CD4, 
CD8 (BD Biosciences) and viability dye (LIVE/DEAD fix-
able yellow dead stain, Invitrogen) were performed in 2 % 
FBS. Intracellular staining was performed after surface 
antibody staining, with the use of Fixation/Permeabiliza-
tion Solution Kit (BD Cytofix/Cytoperm™), followed by 
staining with antibodies targeting p24 (Beckman Coul-
ter, #KC-57). Cells were fixed by 1  % paraformaldehyde 
and analyzed with Cyan ADP FACS machine (DAKO). 
(See figure on next page.) 
Fig. 5 Ablation of CCR5 usage reduces pathogenesis of dual tropic HIV‑1 in a humanized mouse model. a Humanized mice were infected with 
R3A or R3A‑5/6AA as described in “Methods” section. Viral replication was assessed weekly by RT‑qPCR measurement of HIV‑1 genomic RNA in the 
blood. HIV‑1 infection in CD4 T cells was analyzed by intracellular p24 staining of splenocytes isolated from infected mice at 3 weeks post infection 
(wpi). b Total PBMCs in blood, spleen and bone marrow from infected animals were harvested at 3wpi, and CD4 T cell depletion was analyzed by 
FACS staining as described in Fig. 1b. c p24(−) and p24(+) CD4 T cell viability in R3A versus R3A‑5/6AA infection in the infected animal’s spleen and 
bone marrow were analyzed as described in Fig. 1c. *p < 0.05
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Live total cell numbers were counted by Guava Easy-
Cytes after staining with viability dye. %CD4 T cells sur-
vived at a the time point were analyzed as live CD3(+) 
CD8(−) populations in PBMCs. Total live CD4 T cell 
numbers at a given time where calculated using the total 
live cell numbers multiplied by %CD4 T cells in PBMCs. 
Total infected CD4 T cell numbers were calculated using 
total CD4 T cell number multiplied by %p24(+) in live 
CD3(+) CD8(−) cells.
HIV‑1 infection of humanized mice and analysis
DKO-huHSC mice were constructed as previously 
reported [22]. DKO-huHSC mice were infected with 
HIV-1 at 4000 infectious units/mouse by intravenous 
injection. At termination, whole animal’s blood and lym-
phoid organs including spleen and bone marrow were 
harvested as described before [22]. Total lymphocytes 
were isolated from lymphoid organs and red blood cells 
were lysed with ACK buffer, and remaining cells were 
stained and fixed before flow cytometry analysis as 
described above.
RT‑qPCR analysis and HIV‑1 reverse transcriptase activity 
analysis of viral load
Viremia in supernatants from infected PBMC cultures 
or from blood plasma of infected humanized mice was 
analyzed by viral RNA extraction (QIAamp viral RNA 
mini kit, Qiagen), and analyzed by RT-qPCR (Taqman 
One-Step RT-qPCR Master Mix, ABI) using the fol-
lowing primers and probe targeting HIV-1 Gag region: 
765gagF 5′-GGTGCGAGAGCGTCAGTATTAAG-3′; 
911gagR 5′-AGCTCCCTGCTTGCCCATA-3′; probe 
FAM-AAAATTCGGTTAAGGCCAGGGGGAAAGAA-
QSY7 (TAMRA). HIV-1 RT activity was analyzed in the 
infected PBMC supernatant as described before in Lee 
MH et al., J Clinical Microbiology, 1987.
Statistical analysis
The significance of all comparisons was calculated by the 
use of a Student 2-tailed t test, and results were consid-
ered significant when p < 0.05.
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Additional files
Additional file 1: Figure S1. CXCR4 antagonist AMD3100 inhibits R3A 
replication.a PBMCs were treated with the indicated drugs before infec‑
tion with R3A, and viral infection efficiencies were measured by %p24+ 
cells with FACS analysis at 4 days post infection. AMD3100 (2µM) and 
TAK‑779 (5µM) were used at >IC90 dose as determined before in U373‑
CD4‑CCR5/CXCR4 cells. b PBMCs were treated with AMD3100 before 
infection with R3A and maintained after infection. HIV‑1 replication was 
measured by extracellular HIV‑1 reverse transcriptase activity in the cell 
supernatant. c CD4 T cell depletion by R3A in the presence of AMD3100 
was measured by FACS analysis. %CD4 T cells relative to mock infected 
PBMCs are presented.
Additional file 2: Figure S2. Similar infection levels by R3A and R3A‑
5/6AA in PBMCs.a Infectivity of R3A and R3A‑5/6AA HIV‑1 strain was 
measured in CCR5‑expressing (Top) or CXCR4‑expressing (Bottom) U373 
MAGI cells. Viral infectivity was presented as infectious units per ng of p24. 
b PBMCs were infected with 20ng p24 of R3A or R3A‑5/6AA virus stock, 
and viral replication kinetics was analyzed by intracellular p24 staining. 
Representative FACS plots of p24 staining at 6dpi are presented. Sup‑
plementary to Fig. 3a.
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